Erlotinib Completed Phase 0 Trials for Head and Neck Carcinoma Treatment

IndicationsStatusPurposePhase
CompletedTreatment0
clinicaltrials.gov IdentifierTitleDrugs
NCT00601913Erlotinib and Surgery in Treating Patients With Head and Neck Cancer That Can Be Removed by Surgery